The BMI methylation-profile scores, based on 78 probes selected from an MWAS in the larger Framingham Heart Study (M.M.M., unpublished data) but weighted with effect sizes estimated in the LBCs, explained 7.3% of the variation in BMI in the LifeLines DEEP cohort, whereas a profile score based on the effects estimated in the LifeLines DEEP cohort explained 11% of the variation in the LBCs. As before, the methylation-profile scores showed an additive effect with the genetic-profile scores (Figure S4). Compared to the methylation-profile scores derived from the MWAS in the LBCs or LifeLines DEEP cohort, the larger R2 values for the profile scores based on probes identified in the Framingham cohort suggest that the larger sample size in the latter study provided more power to identify additional CpG probes and hence allowed us to explain a higher proportion of variance in BMI.